Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Competing risk analysis*.

From: Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers

      Breast cancer Ovarian cancer
   Unaffected
N (%)
Breast
cancer
N (%)
Ovarian
cancer
N (%)
HR 95% CI P-value HR 95% CI P-value
CDK2NA/B - rs1011970          
BRCA1 GG 3,328 (69.6) 4,424 (69.9) 1,026 (70.1) 1    1   
  GT 1,309 (27.4) 1,710 (27.0) 398 (27.2) 1.03 0.95 to 1.11   1.10 0.95 to 1.26  
  TT 142 (3.0) 194 (3.1) 39 (2.7) 1.09 0.88 to 1.35   0.90 0.61 to 1.32  
  2-df test       0.57    0.35
  per allele     1.04 0.91 to 1.11 0.30 1.04 0.93 to 1.17 0.48
BRCA2 GG 1,972 (68.6) 2578 (67.9) 315 (69.5) 1    1   
  GT 815 (28.4) 1097 (28.9) 129 (28.5) 1.09 0.98 to 1.21   1.07 0.85 to 1.35  
  TT 86 (3.0) 122 (3.2) 9 (2.0) 1.19 0.91 to 1.57   0.84 0.40 to 1.77  
  2-df test       0.15    0.74
  per allele     1.09 1.00 to 1.19 0.05 1.03 0.84 to 1.25 0.81
ZNF365 - rs10995190           
BRCA1 GG 3,408 (71.3) 4,523 (71.5) 1,019 (69.6) 1    1   
  GA 1,258 (26.3) 1,650 (26.1) 410 (28.0) 1.00 0.93 to 1.08   1.12 0.98 to 1.28  
  AA 113 (2.4) 155 (2.5) 35 (2.4) 0.96 0.78 to 1.20   0.90 0.61 to 1.33  
  2-df test       0.94    0.23
  per allele     0.99 0.93 to 1.06 0.88 1.06 0.95 to 1.19 0.32
BRCA2 GG 2,033 (70.4) 2,795 (73.7) 318 (70.2) 1    1   
  GA 794 (27.7) 920 (24.3) 122 (26.9) 0.86 0.78 to 0.96   0.99 0.78 to 1.25  
  AA 55 (1.9) 79 (2.1) 13 (2.9) 1.03 0.74 to 1.43   1.58 0.83 to 3.03  
  2-df test       0.02    0.37
  per allele     0.90 0.82 to 0.99 0.03 1.06 0.87 to 1.31 0.55
ZMIZ1 - rs704010           
BRCA1 CC 1,904 (40.2) 2,493 (40.0) 583 (40.1) 1    1   
  CT 2,172 (45.9) 2,871 (46.0) 665 (45.7) 1.02 0.95 to 1.10   1.01 0.89 to 1.15  
  TT 660 (13.9) 877 (14.1) 206 (14.2) 1.02 0.92 to 1.14   1.01 0.84 to 1.22  
  2-df test       0.67    0.99
  per allele     1.01 0.97 to 1.07 0.58 1.01 0.92 to 1.10 0.90
BRCA2 CC 1,109 (39.0) 1,439 (38.4) 181 (40.1) 1    1   
  CT 1,306 (46.0) 1,774 (47.3) 192 (43.4) 1.06 0.96 to 1.17   0.96 0.76 to 1.20  
  TT 426 (15.0) 538 (14.3) 69 (15.6) 1.00 0.86 to 1.15   1.05 0.77 to 1.43  
  2-df test       0.46    0.81
  per allele     1.01 0.95 to 1.08 0.72 1.01 0.87 to 1.18 0.90
10p15 - rs2380205         
BRCA1 CC 1,183 (32.2) 1,698 (32.1) 438 (33.2) 1    1   
  CT 1,796 (48.9) 2,605 (49.3) 634 (48.1) 0.99 0.91 to 1.08   0.91 0.79 to 1.05  
  TT 696 (18.9) 981 (18.6) 246 (18.7) 1.00 0.90 to 1.12   0.94 0.78 to 1.14  
  2-df test       0.96    0.45
  per allele     1.00 0.95 to 1.06 0.98 0.96 0.87 to 1.06 0.40
BRCA2 CC 872 (32.6) 1,161 (31.8) 143 (33.7) 1    1   
  CT 1,321 (49.4) 1,812 (49.6) 199 (46.9) 1.04 0.94 to 1.16   0.94 0.74 to 1.19  
  TT 481 (18.0) 678 (18.6) 82 (19.3) 1.03 0.90 to 1.18   1.01 0.75 to 1.38  
  2-df test       0.74    0.82
  per allele     1.02 0.95 to 1.09 0.61 1.00 0.85 to 1.16 0.98
11q13 - rs614367         
BRCA1 CC 3,439 (72.3) 4,547 (72.1) 1,111 (76.2) 1    1   
  CT 1,212 (25.5) 1,606 (25.5) 311 (21.3) 1.02 0.94 to 1.11   0.83 0.72 to 0.96  
  TT 109 (2.3) 154 (2.4) 37 (2.5) 1.12 0.91 to 1.39   1.20 0.81 to 1.76  
  2-df test       0.52    0.03
  per allele     1.03 0.91 to 1.10 0.35 0.91 0.80 to 1.03 0.13
BRCA2 CC 2,106 (73.5) 2,716 (71.9) 333 (73.8) 1    1   
  CT 693 (24.2) 981 (26.0) 108 (24.0) 1.05 0.95 to 1.16   0.95 0.74 to 1.21  
  TT 66 (2.3) 83 (2.2) 10 (2.2) 0.96 0.71 to 1.28   0.87 0.46 to 1.63  
  2-df test       0.62    0.84
  per allele     1.03 0.94 to 1.12 0.56 0.94 0.77 to 1.15 0.56
12q24 - rs1292011         
BRCA1 AA 997 (34.1) 1,321 (35.4) 305 (34.9) 1    1   
  AG 1,406 (48.2) 1,765 (47.3) 429 (49.1) 1.00 0.90 to 1.10   1.11 0.93 to 1.31  
  GG 517 (17.7) 645 (17.3) 140 (16.0) 1.01 0.89 to 1.15   0.98 0.78 to 1.24  
  2-df test       0.97    0.39
  per allele     1.00 0.94 to 1.07 0.91 1.01 0.91 to 1.13 0.82
BRCA2 AA 715 (35.0) 907 (35.9) 110 (36.5) 1    1   
  AG 961 (47.0) 1222 (48.4) 137 (45.5) 1.02 0.90 to 1.15   0.94 0.71 to 1.25  
  GG 370 (18.1) 396 (15.7) 54 (17.9) 0.83 0.70 to 0.97   0.89 0.61 to 1.28  
  2-df test       0.03    0.80
  per allele     0.93 0.86 to 1.00 0.07 0.94 0.78 to 1.13 0.51
PTHLH - rs10771399         
BRCA1 AA 3,810 (79.8) 5,179 (81.9) 1,145 (78.4) 1    1   
  AG 909 (19.0) 1078 (17.1) 289 (19.8) 0.89 0.81 to 0.97   1.09 0.93 to 1.26  
  GG 56 (1.2) 65 (1.0) 27 (1.9) 0.86 0.63 to 1.16   1.67 1.05 to 2.64  
  2-df test       0.02    0.06
  per allele     0.90 0.83 to 0.97 6.4 × 10 -3 1.14 1.00 to 1.30 0.06
BRCA2 AA 2,289 (79.7) 3,076 (81.2) 369 (81.5) 1    1   
  AG 545 (19.0) 678 (17.9) 76 (16.8) 0.94 0.84 to 1.06   0.88 0.67 to 1.16  
  GG 37 (1.3) 34 (0.9) 8 (1.8) 0.79 0.49 to 1.26   1.48 0.63 to 3.46  
  2-df test       0.38    0.43
  per allele     0.93 0.84 to 1.04 0.19 0.96 0.75 to 1.23 0.75
9q31.2 - rs865686         
BRCA1 TT 1,935 (40.5) 2,621 (41.5) 605 (41.3) 1    1   
  TG 2,206 (46.2) 2,825 (44.7) 690 (47.1) 0.94 0.88 to 1.01   0.99 0.87 to 1.12  
  GG 633 (13.3) 877 (13.9) 169 (11.5) 1.03 0.93 to 1.15   0.85 0.70 to 1.03  
  2-df test       0.12    0.23
  per allele     1.00 0.95 to 1.05 0.88 0.94 0.86 to 1.03 0.17
BRCA2 TT 1,103 (38.4) 1,576 (41.6) 179 (39.6) 1    1   
  TG 1400 (48.8) 1712 (45.2) 215 (47.6) 0.85 0.77 to 0.94   0.91 0.73 to 1.14  
  GG 367 (12.8) 501 (13.2) 58 (12.8) 0.97 0.84 to 1.12   0.98 0.71 to 1.35  
  2-df test       4.6 × 10 -3    0.70
  per allele     0.94 0.88 to 1.01 0.10 0.97 0.83 to 1.13 0.67
  1. Associations with breast and ovarian cancer risk for BRCA1 and BRCA2 carriers.
  2. *Censoring process described in the methods
  3. HR, hazard ratio